You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-NK-LGL

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive

Recruiting
  • LGLL - Large Granular Lymphocytic Leukemia
  • +13 more
  • Duarte, California
  • +9 more
Aug 9, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

Not yet recruiting
  • NK/T Cell Lymphoma Nos
  • Brentuximab Vedotin in Combination with Tislelizumab
  • (no location specified)
Apr 6, 2022

Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • VT-EBV-N
  • Placebo
  • Busan, Korea, Republic of
  • +7 more
Apr 28, 2022

Immunity, Innate, Colorectal Cancer Trial in Montreal (IVDD for NK cell activity in whole blood)

Terminated
  • Immunity, Innate
  • Colorectal Cancer
  • IVDD for NK cell activity in whole blood
  • Montreal, Quebec, Canada
  • +2 more
Jan 30, 2023

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Miami, Florida
  • +8 more
Aug 1, 2022

Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

Not yet recruiting
  • Extranodal Natural Killer/T-cell Lymphoma
  • circulate free methylated EBV DNA
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 19, 2022

Hematologic Malignancies Trial in Hangzhou (RD13-01 cell infusion)

Completed
  • Hematologic Malignancies
  • RD13-01 cell infusion
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Jan 8, 2022

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Advanced Solid Tumors Trial in Wuxi (Anti-CAR-NK Cells)

Recruiting
  • Advanced Solid Tumors
  • Anti-CAR-NK Cells
  • Wuxi, Jiangsu, China
    Wuxi People's Hospital
Jan 18, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

T-LGL Leukemia, Clpd-Nk Trial in China (thalidomide + prednisone + methotrexate)

Recruiting
  • T-LGL Leukemia
  • Clpd-Nk
  • thalidomide + prednisone + methotrexate
  • Nanning, Guangxi, China
  • +8 more
Jun 26, 2020

Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

Active, not recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Seoul, Korea, Republic of
    81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Sep 22, 2021

Hemophagocytic Syndrome, T/NK-Cell Lymphoma Trial in Zhengzhou (Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine,

Recruiting
  • Hemophagocytic Syndrome
  • T/NK-Cell Lymphoma
  • Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
Aug 3, 2021

NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

Not yet recruiting
  • NHL, Relapsed, Adult
  • +3 more
  • KUR-502
  • (no location specified)
Aug 2, 2022

NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma Trial in San Francisco, Valhalla (Methotrexate, pralatraxate,,

Recruiting
  • NK-Cell Lymphoma
  • +2 more
  • San Francisco, California
  • +1 more
Sep 1, 2021